Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Operations (2016 - 2025)

Agios Pharmaceuticals' Cash from Operations history spans 14 years, with the latest figure at 96213000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 27.75% year-over-year to 96213000.0; the TTM value through Dec 2025 reached 372977000.0, up 4.33%, while the annual FY2025 figure was 372977000.0, 4.33% up from the prior year.
  • Cash from Operations reached 96213000.0 in Q4 2025 per AGIO's latest filing, down from 88151000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 9141000.0 in Q4 2021 to a low of 163998000.0 in Q3 2021.
  • Average Cash from Operations over 5 years is 84122200.0, with a median of 80671000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: surged 109.33% in 2021, then plummeted 823.8% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 9141000.0 in 2021, then tumbled by 823.8% to 66163000.0 in 2022, then dropped by 9.56% to 72488000.0 in 2023, then crashed by 83.71% to 133167000.0 in 2024, then rose by 27.75% to 96213000.0 in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Cash from Operations are 96213000.0 (Q4 2025), 88151000.0 (Q3 2025), and 77124000.0 (Q2 2025).